Compare Dollar Tree, Inc. (DLTR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Dollar Tree, Inc. trades at $118.29 (market cap $22.26B), while State Street SPDR S&P Biotech ETF trades at $153.87 (market cap $10.11B). The key difference: Dollar Tree, Inc. is far larger — about 2.2× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Dollar Tree, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| DLTR | XBI | |
|---|---|---|
Market Cap | $22.26B | $10.11B |
Volume | 2,317,428 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $141.21 | $169.55 |
52-Week Low | $86.80 | $104.99 |
Typical Hold Time | 58 Days | 38 Days |
Enterprise Value | $28.87B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $117.42, up 0.96% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 45.87% ROE and trades at a modest P/E of 14.54. Recent news highlights strategic initiatives and store expansions supporting growth, though margin risks from tariffs and reinvestment remain a focus.
The outlook is positive with a consensus price target of $139.33, implying 18.7% upside, but investors face risks from volatile margins, high debt levels, and competitive pressures. Earnings improvement and institutional buying provide support, yet the stock's recent decline of 17.9% over the past month underscores near-term challenges.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
